• 1
    Ueki T, Mizuno M, Uesu T et al. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC). Clin Exp Immunol 1996; 104:286292.
  • 2
    Halstensen TS, Mollnes TE, Brandtzaeg P. Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology 1989; 97:1019.
  • 3
    Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut 1992; 33:902908.
  • 4
    Halstensen TS, Mollnes TE, Fausa O, Brandtzaeg P. Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. Gut 1989; 30:361366.
  • 5
    Halstensen TS, Brandtzaeg P. Local complement activation in inflammatory bowel disease. Immunol Res 1991; 10:485492.
  • 6
    Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med 1990; 322:13451349.
  • 7
    Scheinin T, Bohling T, Halme L, Kontiainen S, Bjorge L, Meri S. Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum Pathol 1999; 30:14271430.
  • 8
    Berstad AE, Brandtzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 1998; 42:522529.
  • 9
    Uesu T, Mizuno M, Inoue H, Tomoda J, Tsuji T. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis. Lab Invest 1995; 72:587591.
  • 10
    Lu F, Fernandes SM, Davis AE, 3rd. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2010; 298:G878883.
  • 11
    Lin F, Spencer D, Hatala DA, Levine AD, Medof ME. Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease. J Immunol 2004; 172:38363841.
  • 12
    Aomatsu T, Imaeda H, Takahashi K et al. Neutralization of complement component C5 ameliorates the development of dextran sulfate sodium (DSS)-colitis in mice. J Clin Biochem Nutr 2013; 52:7275.
  • 13
    Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J Biol Chem 2006; 281:3908839095.
  • 14
    Wende E, Laudeley R, Bleich A et al. The complement anaphylatoxin C3a receptor (C3aR) contributes to the inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice. PLOS ONE 2013; 8:e62257.
  • 15
    Chen G, Yang Y, Gao X et al. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis. Lab Invest 2011; 91:472483.
  • 16
    Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, Taylor SM. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol 2003; 171:55145520.
  • 17
    Johswich K, Martin M, Bleich A et al. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:18121823.
  • 18
    Deguchi Y, Andoh A, Inatomi O et al. Development of dextran sulfate sodium-induced colitis is aggravated in mice genetically deficient for complement C5. Int J Mol Med 2005; 16:605608.
  • 19
    Schepp-Berglind J, Atkinson C, Elvington M, Qiao F, Mannon P, Tomlinson S. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol 2012; 188:63096318.
  • 20
    Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108:12681276.
  • 21
    Atkinson C, Song H, Lu B et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005; 115:24442453.
  • 22
    Khan MZ, Prebeg Z, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Release 1999; 58:215222.
  • 23
    Larsen C, Harboe E, Johansen M, Olesen HP. Macromolecular prodrugs. XVI. Colon-targeted delivery – comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res 1989; 6:995999.
  • 24
    Larsen C, Jensen BH, Olesen HP. Stability of ketoprofen–dextran ester prodrugs in homogenates of various segments of the pig GI tract. Acta Pharm Nord 1991; 3:4144.
  • 25
    Varshosaz J, Emami J, Tavakoli N et al. Synthesis and evaluation of dextran–budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm 2009; 365:6976.
  • 26
    van Dijk-Wolthuis WNE, Franssen O, Talsma H, van Steenbergen MJ, Kettenes-van den Bosch JJ, Hennink WE. Synthesis, characterization, and polymerization of glycidyl methacrylate derivatized dextran. Macromolecules 1995; 28:63176322.
  • 27
    Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008; 181:80688076.
  • 28
    Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol 2013; 734a:137154.
  • 29
    Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007; 56:25.
  • 30
    Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013; 6:269293.